| 7.42 0.61 (8.96%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.14 |
1-year : | 10.68 |
| Resists | First : | 7.82 |
Second : | 9.14 |
| Pivot price | 7.21 |
|||
| Supports | First : | 6.95 |
Second : | 6.41 |
| MAs | MA(5) : | 6.96  |
MA(20) : | 7.25 |
| MA(100) : | 7.41 |
MA(250) : | 6.36 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 46.4 |
D(3) : | 36.6 |
| RSI | RSI(14): 51.3 |
|||
| 52-week | High : | 9.31 | Low : | 3.85 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EOLS ] has closed below upper band by 31.3%. Bollinger Bands are 27.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.45 - 7.48 | 7.48 - 7.51 |
| Low: | 6.76 - 6.8 | 6.8 - 6.84 |
| Close: | 7.35 - 7.42 | 7.42 - 7.48 |
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Thu, 05 Nov 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS - PR Newswire
Thu, 05 Nov 2026
Evolus Inc (EOLS) (Q3 2026) Earnings Call Highlights: Fourth Consecutive Positive Adjusted ... - Yahoo Finance
Wed, 04 Nov 2026
What Evolus (EOLS) Said on Its Q3 Earnings Call - Yahoo Finance
Wed, 04 Nov 2026
Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance
Mon, 12 Oct 2026
EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law - Business Wire
Fri, 02 Oct 2026
Evolus gets FDA warnings over Jeuveau IG post (EOLS:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 66 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 11.2 (%) |
| Held by Institutions | 77.8 (%) |
| Shares Short | 6,410 (K) |
| Shares Short P.Month | 5,530 (K) |
| EPS | -0.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.57 |
| Profit Margin | -9.6 % |
| Operating Margin | -7.5 % |
| Return on Assets (ttm) | -4.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 13 % |
| Gross Profit (p.s.) | 3.24 |
| Sales Per Share | 4.91 |
| EBITDA (p.s.) | -0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | 13 (M) |
| PE Ratio | -15.46 |
| PEG Ratio | 0 |
| Price to Book value | -13.02 |
| Price to Sales | 1.5 |
| Price to Cash Flow | -185.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|